Finasteride is a synthetic compound classified as a 5-alpha reductase inhibitor. It is not an endogenous hormone but is chemically synthesized for therapeutic purposes. Finasteride is primarily used in the management of androgen-dependent conditions such as androgenetic alopecia (AGA) and benign prostatic hyperplasia (BPH). It is marketed under brand names like Propecia and Proscar. Researchers have found that finasteride effectively reduces the levels of dihydrotestosterone (DHT), a potent androgen involved in hair loss and prostate enlargement. The primary physiological role of finasteride is to inhibit the conversion of testosterone to DHT by targeting the 5-alpha reductase enzyme, specifically the type II isoenzyme. This action results in decreased DHT levels, which is beneficial in conditions like AGA and BPH. Finasteride's mechanism of action involves the inhibition of the 5-alpha reductase enzyme, which prevents the conversion of testosterone into dihydrotestosterone (DHT). This reduction in DHT levels leads to decreased androgenic activity in tissues such as the scalp and prostate, thereby mitigating hair loss and reducing prostate size. Pharmacokinetically, finasteride has an oral bioavailability, with a plasma half-life of approximately 4.5 hours. It is metabolized primarily in the liver and excreted in urine and feces. Clinically, finasteride is approved by the FDA for the treatment of male pattern hair loss and BPH. It is available in oral formulations, with 1 mg/day commonly prescribed for AGA and 5 mg/day for BPH. Despite its efficacy, researchers have observed side effects such as sexual dysfunction and potential neuropsychiatric effects, which have been noted in post-marketing surveillance and led to updates in safety labeling.